TKI Selection and Sequencing Considerations in CML and ALL

Michael J. Mauro, MD, discusses his approach to TKI use in chronic myeloid leukemia and how new FDA approvals inform his practice.

Michael Mauro, MD, details the FDA approval of the small-molecule formulation of dasatinib and other alternate TKI formulations in chronic myeloid leukemia.

Michael J. Mauro, MD, discusses the variety of TKIs available for chronic myeloid leukemia management and how to navigate new formulations.

Jorge Cortes, MD, discusses the variety of long-term patient goals in chronic myeloid leukemia and how prioritizing them leads to different TKI selections.

Jorge Cortes, MD, discusses available TKIs and how to navigate optimal treatment selection for patients with chronic myeloid leukemia.